UCL spinout Engitix plans to develop therapeutics for liver fibrosis and certain cancers based on its targeted drug discovery platform.

Engitix, a UK-based drug discovery spinout from University of College London (UCL), closed a £5m ($6.4m) series A round yesterday led by an unnamed private investor. Founded in 2016, Engitix has developed a drug discovery platform which uses specific engineered tissues to find treatments that target liver fibrosis, a condition affecting the liver’s function due…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.